학술논문
Association between CYP3A4, CYP3A5and ABCB1Genotype and Tacrolimus Treatment Outcomes Among Allogeneic HSCT Patients
Document Type
Article
Author
Source
Pharmacogenomics; January 2024, Vol. 25 Issue: 1 p29-40, 12p
Subject
Language
ISSN
14622416; 17448042
Abstract
Aim:Successful treatment with tacrolimus to prevent graft versus host disease (GVHD) and minimize tacrolimus-related toxicities among allogeneic hematopoietic cell transplantation (alloHCT) recipients is contingent upon quickly achieving and maintaining concentrations within a narrow therapeutic range. The primary objective was to investigate associations between CYP3A4, CYP3A5or ABCB1genotype and the proportion of patients that attained an initial tacrolimus goal concentration following initiation of intravenous (iv.) and conversion to oral administration. Materials & methods:We retrospectively evaluated 86 patients who underwent HLA-matched (8/8) related donor alloHCT and were prescribed a tacrolimus-based regimen for GVHD prophylaxis. Results & conclusion:The findings of the present study suggests that CYP3A5genotype may impact attainment of initial therapeutic tacrolimus concentrations with oral administration in alloHCT recipients.